Core Points - Shanghai Aopumai Biotechnology Co., Ltd. announced that its wholly-owned subsidiary, Shanghai Silun Biotechnology Co., Ltd., successfully passed the EU Qualified Person (QP) audit, receiving a compliance audit report [1][2] - The audit covered various aspects including quality management, production management, facilities, material systems, and packaging and labeling systems, confirming that Silun Biotechnology meets current EU GMP requirements [1] - This achievement establishes a solid foundation for the company's high-quality research and production services in the large molecule biopharmaceutical sector, facilitating further expansion into EU and international markets [2] Company Impact - The successful QP audit indicates that the quality management system of Silun Biotechnology has reached the standards required by EU GMP regulations [2] - The company has developed a comprehensive CDMO service platform for large molecule biopharmaceuticals, providing full-process support from early research to commercial production [1] - The passing of the QP audit is not expected to have a significant impact on the company's current performance [2]